Fully Human, Whole IgGs
Adimab’s technology utilizes fully human whole IgGs, and therefore does not suffer from limitations of antibody fragments such as Fabs or scFvs.  This significantly reduces the time and effort associated with multiple expression systems and reformatting steps required to deliver a human full IgG.  In addition, antibodies identified in Adimab’s system can undergo greater characterization very early in the development process, such as expressability, biophysical properties (including affinity measurements and aggregation), as well as the potential to disrupt protein-protein interactions (e.g. with ligands or competing IgGs). Whole IgGs also provide a better assessment of the therapeutic/biological function of the therapeutic antibody.  For example, an IgG, being divalent, can cross link a receptor and activate it whereas a monovalent scFv or Fab cannot.  Also, an IgG can sterically block interaction with a ligand where a Fab may not, and an IgG may cause receptor down regulation where a Fab does not.

Rapid Process
Adimab’s technology can generate large panels of high affinity human antibodies in a short timeframe.  For a typical project, we generally deliver purified, whole IgGs (at least 50 micrograms per clone) to our partners within 8 weeks of initiating a selection campaign.  This can dramatically reduce the development time and cost for developing a therapeutic product.

Highly Flexible Process
Adimab’s process allows for great flexibility in designing selection strategies.  Many reagents (e.g. natural ligands or co-receptors, an existing non-human antibody to the target, etc.) can be used to identify panels of therapeutically relevant IgGs.  In addition, the ability to utilize FACS analysis during the selection process enables a variety of broader characterizations to be done early in the discovery process – this may include assays such as epitope binning and competitive binding/inhibition, as well as species cross-reactivity. FACS analysis can be used to examine antibody libraries at 10,000 clones per second, giving Adimab unprecedented control and flexibility over the selection criteria that are used to identify a therapeutic antibody with desired properties.  For example, the desired antibody, in order to be therapeutically relevant may have to: (i) compete with a particular ligand, (ii) be cross-reactive with other species of pre-clinical importance such as mouse or cynomolgus monkey.

Selecting for Expression
Determining expression levels of unique IgGs is an important part of the lead identification process.  Adimab’s technology allows for the selection of high expressing IgGs at a very early stage.  Due to the number of IgGs generated against each target, low-expressing IgGs are discarded.  Other technologies are unable to assess IgG expressability at such an early stage, often leading to downstream issues that result in costly delays for therapeutic programs.